Tan Aik Na 4

4 · Wave Life Sciences Ltd. · Filed Dec 10, 2025

Form 4

Period: 2025-12-08

Director

Transactions

Sale
Ordinary Shares
2025-12-08$12.75/sh−7,494$95,549→ 32,894 total
Exercise/Conversion
Ordinary Shares
2025-12-08$5.37/sh+32,230$173,075→ 57,630 total
Sale
Ordinary Shares
2025-12-08$12.75/sh−15,000$191,250→ 42,630 total
Sale
Ordinary Shares
2025-12-08$15.00/sh−17,230$258,450→ 25,400 total
Exercise/Conversion
Ordinary Shares
2025-12-08$4.58/sh+45,000$206,325→ 70,400 total
Sale
Ordinary Shares
2025-12-08$12.75/sh−20,000$255,000→ 50,400 total
Sale
Ordinary Shares
2025-12-08$15.00/sh−25,000$375,000→ 25,400 total
Exercise/Conversion
Ordinary Shares
2025-12-08$3.50/sh+21,000$73,500→ 46,400 total
Sale
Ordinary Shares
2025-12-08$12.75/sh−21,000$267,750→ 25,400 total
Exercise/Conversion
Share Option (right to buy)
2025-12-08−32,230→ 0 total
Exercise: $5.37Exp: 2029-08-12→ Ordinary Shares (32,230 underlying)
Exercise/Conversion
Share Option (right to buy)
2025-12-08−45,000→ 0 total
Exercise: $4.58Exp: 2028-08-07→ Ordinary Shares (45,000 underlying)
Exercise/Conversion
Share Option (right to buy)
2025-12-08−21,000→ 0 total
Exercise: $3.50Exp: 2027-08-15→ Ordinary Shares (21,000 underlying)

Footnotes (2)

[F1]The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
[F2]These share options are fully vested.

Documents

1 file